GEMIGLIPTIN MARKET ANALYSIS

Name: Gemigliptin Market News
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy

Gemigliptin Market, By Type of Drug (Gemigliptin Monotherapy, Gemigliptin Combination Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics and Outpatient Facilities, Others), By Patient Demographics (Adult Population, Geriatric Population), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East)

Recent Developments

In April 2023, LG Chem, a South Korea-based chemical company, announced the launch of Zemidapa, a combination therapy containing DPP-4 inhibitor Zemiglo (gemigliptin) and SGLT-2 inhibitor Forxiga (dapagliflozin).
In December 2022, LG Chem confirmed the safety and efficacy of Zemidapa as a dual add-on therapy for type 2 diabetes patients who do not respond well to metformin standard diabetes treatments in a phase 3 clinical trial.
In February 2022, Daewoong Pharmaceutical Co., Ltd., a South Korea-based pharmaceutical company, announced the topline results of the phase 3 clinical trial for a triple combination therapy of Enavogliflozin, a new antidiabetic drug with the mechanism of SGLT-2 inhibitor, with metformin and gemigliptin.